Introduction {#sec1}
============

Tuberculosis (TB), as an infectious disease is caused by *Mycobacterium* species in humans ([@bib18]). The etiological agent of the disease is most often *Mycobacterium tuberculosis* (MTB), and less commonly other species in the *Mycobacterium tuberculosis* complex (MTBC). *Mycobacterium* species other than these species are classified as non-tuberculosis mycobacteria (NTMs) ([@bib29]). In recent years, the incidence of diseases caused by NTMs has increased due to the increasing number of immunosuppressed patients ([@bib23]).

Members of MTBC are usually transmitted to susceptible persons through airborne means such as coughing, sneezing, or speaking by patients suffering from infectious tuberculosis (Churchyard et al. 2016). The successful establishment of an infection in the lungs is influenced by various factors such as phagocytosis of the bacilli, their intracellular multiplication, latency, and active lung infection ([@bib2]). However, there is no clear evidence that NTMs are transmitted from either person to person or from animals to people. Therefore, the transmission of NTMs is probably through individual contacts with the source of infection (Churchyard et al. 2016).

Since the treatment of *Mycobacterium* species depends on the correct identification of the isolate, mycobacteriological tests that are leading to the identification are crucial. Methods that include direct microscopic acid-fast bacilli detection (AFB), growth on the solid or liquid media, and biochemical tests continue to play significant roles in the identification of mycobacteria ([@bib12]).

Treatment and prophylaxis of tuberculosis differ from most other bacterial infections. In general, patients should receive multiple antibiotic treatments for at least 6 to 9 months ([@bib19]). The World Health Organization (WHO) recommends the combined use of 1^st^-line drugs in the initial treatment of tuberculosis. However, anti-tuberculosis drug resistance remains a significant problem. Of the primary anti-tuberculosis drugs, isolates showing at least isoniazid (INH) and rifampin (RIF) resistance are defined as Multiple Drug-Resistant Tuberculosis (MDR-TB) ([@bib30]).

In this study, we aimed to document *Mycobacterium* species isolated in a large metropolitan tertiary care hospital in Turkey. The laboratory procedures used to isolate the organisms were also compared. Similarly, the resistance rates to the 1^st^-line anti-tuberculosis drugs were determined. The ultimate aim was to compare these data with the earlier studies and to provide the frame of reference for future studies.

Experimental {#sec2}
============

Materials and Methods {#sec3}
---------------------

Ethical approval was provided from the Ethics Committee of Medical School, Bezmialem University, Istanbul, Turkey (10.09.2019/16--302).

Our facility is a 700-bed academic hospital providing tertiary health care in Istanbul city centre, and 7,480 patients with pre-diagnosis of tuberculosis admitted to Bezmialem University Medical Faculty Hospital between September 2015 and June 2019 were included in the study. Between the dates indicated, 7,480 clinical specimens were sent to the Clinical Microbiology Laboratory with a preliminary diagnosis of tuberculosis. Two hundred seventy-eights of these samples were positive for *Mycobacterium* species in at least one of the methods studied. Only the first positive isolates from the same patient were included in the study.

Homogenization and decontamination of sputum, bronchoalveolar lavage (BAL), fasting gastric juice, urine, and abscess materials were performed according to published guidelines. Sterile body fluids such as cerebrospinal fluid (CSF), peritoneal and pleural fluid, and tissue samples were tested without decontamination. N-acetyl-L-cysteine-4% sodium hydroxide-1.47% sodium citrate (NALC-NaOH) method was used for decontamination and homogenization of the samples. Five to ten ml of each clinical sample was mixed with an equal volume of NALC-NaOH solution. The mixture was transferred to tubes and vortexed for not more than 30 seconds. The tubes containing the mixture were allowed to stand at room temperature for 15 minutes. Fifty ml of phosphate buffer (0.067 M, pH = 6.8) was added to each tube containing the mixture, and the tubes were centrifuged at 3,000 g for 15 minutes. The resulting precipitates were diluted with 1--2 ml of phosphate buffer (pH = 6.8), and smears were prepared from these precipitates. The smears were stained by Erlich-Ziehl-Neelsen (EZN) (GBL Rose Biology Laboratory, Istanbul) method and examined microscopically under immersion oil.

**Isolation of *Mycobacterium* species**. For all the samples, both liquid and solid media are used for culture. Therefore, any isolate growing either on one of these media were used in identification studies. In some patients, multiple specimens were submitted for culture, and multiple cultures were positive for growth. In those patients, the very first isolate was used in the study.

For the liquid culture of mycobacteria, a *Mycobacterium* Growth Indicator Tube (BD MGIT-960, BD, Sparks, MD, USA) system was utilized, and the procedure suggested by the manufacturer was followed. Briefly, oleic acid-albumin-dextrose-catalase (OAOC) was added to the culture medium and as antimicrobial agents, polymyxin B (50 U/ml), azlocillin (10 mcg/ml), nalidixic acid (20 mcg/ml), trimethoprim antibiotic mixture (PANTA, Becton Dickinson, Sparks, MD, USA; 5.0 mcg/ml), and amphotericin B (5.0 mcg/ml) were added. 0.5 ml of the samples from decontaminated clinical mixtures was inoculated into the culture medium, and the culture bottles were incubated for six weeks at 37°C. Samples were considered negative if no growth signal was obtained by the end of this incubation period.

Simultaneous cultivation of the samples on solid media was carried out on Löwenstein-Jensen (LJ) slants (Becton Dickinson, USA). LJ tubes were evaluated daily for 42 days, and the cultures were terminated by 42^nd^ day if no colonies observed. The presence of acid-resistant bacilli was screened by EZN staining from positive cultures.

**Identification of *Mycobacterium* species**. When MGIT-960 instrument signaled positivity, firstly, an EZN stain was performed to screen for AFB, and the positive tubes were inoculated on blood agar medium (Becton Dickinson, USA) containing 5% sheep blood, and the growth was examined to rule out a contaminating bacterial species. Samples were also inoculated onto the LJ medium for future susceptibility testing. After the growth on either solid or liquid media, the identification was performed using the MPT64 immunochromatographic test (BD MGIT TBc Identification Test, Becton Dickinson, Sparks, USA).

In the study, *M. tuberculosis* isolates were identified at the 'complex' level, and no further identification was performed, and therefore, isolates were designated as *M. tuberculosis* complex (MTBC). Non-tuberculous mycobacteria (NTMs) species were identified by the Turkish Public Health Laboratory through a commercial molecular assay (GenoType *Mycobacterium* CM, Hain Lifescience GmbH, Nehren, Germany).

**Antimycobacterial susceptibility tests**. The susceptibilities of MTBC strains to isoniazid (INH), Streptomycin (SM), Rifampicin (RIF), and Ethambutol (ETM) were investigated. For this aim, a commercial susceptibility test method (BD BACTEC MGIT-960 SIRE) was used. The concentrations of the drugs in the testing kit were as follows: SM at 1.0 μg/ml, INH at 0.1 μg/ml, RIF at 1.0 μg/ml, ETM at 5.0 μg/ml. The definitions of the multidrug resistance were that of the commercial test kit (BD BACTEC MGIT-960 SIRE).

**Study design and statistical analysis**. This study was conducted as a retrospective clinical study. Data analysis was performed using SPSS 20.0 software pack (SPSS Inc., USA).

Results {#sec4}
=======

In 278 (3.7%) of 7,480 clinical specimens from patients with suspected tuberculosis, one type of *Mycobacterium* species was isolated. Of the patients with *Mycobacterium* species, 123 (44.2%) were female, 155 (55.8%) were male.

The type of specimens from which MTBC's were isolated was as follows: 198 respiratory tract samples (sputum, BAL and tracheal aspirate), 29 tissue specimens (lymph node biopsy, etc.), 22 sterile body fluids (pleura, peritoneum, CSF), 11 fasting gastric fluid, 11 abscesses, and seven urine samples.

In our study, the AFB positivity was 1.4% (104/7,480), and the culture positivity (LJ and/or MGIT-960) was 3.7% (278/7,480) in the clinical samples of patients with suspected tuberculosis. The culture positivity was 3.4% for LJ (254/7,480) and 3.7% for MGIT-960 (278/7,480). The contamination rate in cultures was 9% (675/7,480) for LJ and 7% (525/7,480) for MGIT-960. In the study, all strains identified as MBTC or NTMs were identified as the same species by both methods.

During the study period, PCR assay was performed for 24 patients' samples upon request from the ordering clinics. A commercial automated Real-time PCR assay (QIAGEN Benelux B.V. The Netherlands) was used at a reference laboratory. Out of these 24 samples, five (20.8%) were positive. PCR positive samples were also positive in liquid (MGIT-960) and solid (LJ) culture methods as studied in house, but only three were positive by AFB. One of the samples negative by PCR (19 patients) was positive by the AFB staining, and 17 out of these 19 specimens were positive on solid media (LJ); all 19 were positive in liquid (MGIT-960) culture.

Two hundred thirty-three (MTBC) and 45 (NTMs) strains were positive by liquid (MGIT-960) or solid (LJ) culture methods. NTMs distribution was as follows: 11 (24.5%) isolates were of *Mycobacterium fortuitum* group, eight (17.8%) of *Mycobacterium abscessus* complex, five (11.1%) of *Mycobacterium simiae*, five (11.1%) of *Mycobacterium lentifilavum*, four (8.9%) of *Mycobacterium chelonae*, four (8.9%) of *Mycobacterium intracellulare*, three (6.7%) of *Mycobacterium gordonae*, two (4.4%) of *Mycobacterium avium* spp., two (4.4%) of *Mycobacterium kansasii*, and one (2.2%) of *Mycobacterium heckeshornense*.

The most MTBC isolates were from respiratory specimens; 120 from sputum, 35 from BALs, and four from tracheal aspirates. The remaining MTBC were recovered from different specimen types. Of the total 45 isolated NTMs strains, 37 were isolated from sputum samples. The number and the types of specimens from which mycobacteria were isolated are presented in Table [I](#tbl1){ref-type="table"}.

###### 

Number, species, AFB positivity and distribution of Mycobacterial strains according to clinical samples.

![](pjm-69-2-185-t001)

                                 AFB     MTBC     NTMs
  ------------------------------ ------- -------- -------
  Respiratory                    198       98     159
        Sputum                   157       89     120
        Bronchoalveolar lavage     37        7      35
        Tracheal aspirate            4       2        4
  Tissue                           22        3      21
        Lymph Node Biopsy          12        2      12
        Other Tissues              10        1        9
  Sterile body fluid               22        --     22
        Pleura                     13        --     13
        BOS                          6       --       6
        Peritoneum                   3       --       3
  Abscess                          18        3      17
  Fasting gastric fluid            11        --       9
  Urine                              7       --       5
  Total                          278     104      233

In the study, the AFB was observed in 98 respiratory patient samples. We performed AFS for the patient respiratory samples as well as the growing microorganisms in the culture. However, 198 respiratory samples grew *Mycobacterium* species that were confirmed as acid-fast organisms by staining.

In all 104 patients, the AFB positive samples (respiratory, tissue, sterile body fluid), at least one type of *Mycobacterium* species was isolated on either solid or in liquid culture methods. Sixty-six (63.5%) of the AFB positive samples were obtained from male subjects, 38 (36.5%) were from females, and the mean age was 43.16 years old (females, mean age 37.55, males -- 46.4 years old).

When the age distribution of the patients was examined, a bi-modal distribution was observed. The number of patients diagnosed with tuberculosis peaked twice between the ages of 20--31 and 60--71. Similarly, isolations of MTBC peaked twice in the patients of 20--31 and 60--71 age range. The isolation of NTMs species was also prominent in the 0--11 age range. The distribution of Mycobacterial strains according to age groups is presented in Fig. [1](#fig1){ref-type="fig"}.

![Distribution of *Mycobacterial* strains according to age groups.](pjm-69-2-185-g001){#fig1}

Of the 233 MTBC strains isolated in the study, 182 (78.1%) were susceptible to all 1^st^-line anti-tuberculosis drugs, while 51 isolates (21.9%) were resistant to at least one of the 1^st^-line anti-tuberculosis drugs tested (Table [II](#tbl2){ref-type="table"}). Total drug resistance rates for INH, SM, RIF, and ETM were 16.7% (n = 39), 14.6% (n = 34), 3% (n = 7), and 0.8% (n = 2), respectively. The highest rates of resistance were observed to the pair of INH + SM (n: 22, 9.4%), and the highest rates of resistance to three drugs were against INH + SM + RIF (n = 73%). Seven rifampin-resistant strains were also resistant to INH and SM. One of the strains was resistant to four 1^st^-line anti-tuberculosis drugs. In our study, the rate of MDR-TB was 13.7% (7/51) among resistant strains and 3% (7/233) among all strains isolated.

###### 

Number and proportion of resistant MTBC strains by years.

![](pjm-69-2-185-t002)

  -----------------------------------------------------------------------------------------------
                            2015\      2016\      2017\      2018\      2019\      Total\
                            (n : 14)   (n : 45)   (n : 66)   (n : 78)   (n : 30)   (n : 233, %)
  ------------------------- ---------- ---------- ---------- ---------- ---------- --------------
  Sensitive to all drugs      11         42         49         61         19       182

  INH                           2          3        13         12           9        39

  SM                            2          1        11         12           8        34

  RIF                           1      --             2          2          2          7

  EMB                       --         --         --             1          1          2

  İNH + SM                      2          1          8          7          5        23

  INH + RIF + SM (MDR-TB)       1                     2          2          2          7
  -----------------------------------------------------------------------------------------------

AFB -- Acid-fast bacilli; MTC -- *Mycobacterium tuberculosis* complex; NTMs -- Non-tuberculosis mycobacteria

In the present study, 21.4% of MTBC isolates in 2015, 6.7% in 2016, 25.8% in 2017, 21.8% in 2017, 36.7% in 2018, and 36.7% in 2017 were tested against 1^st^-line anti-tuberculosis drugs. As the number of strains isolated in 2017 and 2018 increased, so did the number of resistant strains. However, this increase was not statistically significant (*p* \< 0.05). The number and ratio of isolated resistant MTBC strains by years are presented in Table [II](#tbl2){ref-type="table"}.

The number of *M. tuberculosis* isolates at different age groups was presented in Fig. [1](#fig1){ref-type="fig"}. Accordingly, the numbers of TB isolated at different age groups demonstrated a bi-model distribution peaking at third and seventh decade of life. Possible differences between various age groups were analyzed by the Chi-square test, and in both decades, the rates of *M. tuberculosis* isolations were significantly different.

Discussion {#sec5}
==========

TB remains a major public health problem throughout the world. According to the 2018 report of the World Health Organization, it was estimated that in 2017 approximately 10 million people suffered from TB, and approximately 1.5 million people have died ([@bib30]). The determination of the presence of the etiological agent and correct identifications are important to prevent the spread of tuberculosis. Therefore, it is necessary to isolate, determine the type, and to assess the drug resistance of *Mycobacterium* species ([@bib12]).

Direct microscopic examination of smears is rapid and relatively practical and, therefore, is preferred despite low rates of sensitivity in detecting bacilli ([@bib12]). Patients positive on direct microscopic examination are considered to be both more contagious and exhibit a fast progression to clinical disease. Consequently, a direct microscopic examination is recommended, especially in patients with pulmonary tuberculosis ([@bib28]).

In our study, the AFB positivity was 1.4% (104/7,480), and culture positivity (LJ and/or MGIT-960) was 3.7% (278/7,480) in patients with suspected tuberculosis. Overall, MTBC detection rate was 3.1% (233/7,480). Similarly, MTBC detection rate was between 2.1% and 11% in many studies ([@bib3]; [@bib7]; [@bib12]).

Today, culture is the standard gold method for the detection of mycobacteria ([@bib11]). World Health Organization recommends the use of liquid media for *M. tuberculosis* culture ([@bib31]). In other studies, it has been reported that the liquid medium was superior in recovering mycobacteria over solid media ([@bib8]; [@bib14]). In the current investigation, mycobacteria were detected in 3.7% (278/7,480) liquid cultures (MGIT-960) and 3.4% (254/7,480) solid (LJ) cultures.

Age distribution of TB patients is an important parameter reflecting the control of TB in the community. While the disease peaks in advanced ages in populations that implement effective TB control programs, in populations where the control programs are lax, the disease peaks at younger ages ([@bib10]). In some studies, the TB is seen mostly in advanced ages ([@bib5]); however, in an earlier Turkish study ([@bib10]), it was reported two peaks of the TB prevalence in the age group 15--24 and over 65 years old. Similarly, we noticed that the number of patients diagnosed with tuberculosis peaked twice between the ages of 20--31 and 60--71 years. These results suggest that the Turkish population is composed of mixed communities where both loose and effective TB control efforts are exerted.

The isolation rate of mycobacteria (NTMs) other than the *M. tuberculosis* complex is increasing throughout the world ([@bib17]). To date, more than 160 NTMs species have been identified, and approximately one third is associated with diseases in humans. It has been shown to cause serious clinical consequences, especially in people with immunodeficiency ([@bib16]). It has been reported that the distribution of NTMs species varies according to geographical regions and demographic characteristics of affected patients ([@bib25]).

In our study, NTMs were isolated from 45 patients. Among NTMs, *M. fortuitum* group (11 isolates), and *M. abscessus* complex (eight isolates) were the most common mycobacteria. In the US study, Spaulding et al. ([@bib25]) reported that other than MAC, *M. abscessus*/*M. chelonae*, and *M. fortuitum* were the most common isolated NTMs species. In other investigations, the frequencies among NTMs species varied significantly according to geographical regions. In a study conducted in China, [@bib16] found that more than half (59.66%) of 523 NTMs isolates were *M. avium*, and *M. intracellulare*. In this study, rapid growers such as *M. abscessus* and *M. fortuitum* were more frequent. The number MAC isolates were not as high as the others ([@bib16]; [@bib25]). Many factors could be accounted for this difference. The discrepancies in the number of people with immunodeficiency could be one factor since immunodeficiency seems to be an underlying risk factor for MAC infection. TB is a disease that should be treated with proper drug regimens to be administered to patients. The increased drug resistance complicates the treatment and impairs control of the disease. In many studies, resistance rates to commonly used 1^st^-line anti-tuberculosis drugs have been reported to be between 10--25% for INH, 3--16% for RIF, 0.7--19% for SM, and 0.7--10% for ETM ([@bib9]; [@bib24]; [@bib7]; [@bib1]; [@bib20]). Similarly, in this report, resistances to 1^st^-line anti-tuberculosis drugs of INH, SM, RIF and ETM were 16.7%, 14.6%, 3%, and 0.8%, respectively. These data argue that the rate of resistance in this country follows trends not unlike those of other countries.

In many studies, it has been reported that resistance to INH and RIF are often, but resistance to other anti-tuberculosis drugs may also develop ([@bib6]; [@bib21]). However, in some studies, similar to our study, resistance to INH and SM was higher, and RIF and ETM resistances were reduced. In these studies, there were significant differences between the resistance rates by region, and the primary anti-tuberculosis drugs with the highest resistance rates were INH and SM ([@bib12]; [@bib15]; Sani et al. 2015; [@bib26]). It is thought that higher rates of INH and SM resistance compared to other primary anti-tuberculosis drugs may be related to the more frequent use of these drugs in both prophylaxis and treatment. Similar arguments could be put forth for this country.

The Report of the Turkish Association of Anti-TB Campaign published in 2018 indicated that in 2016, the drug susceptibility test results were surveyed for 6,037 MTC, and resistance to at least one drug was detected in 19.2% isolates. According to this report, 3.3% of the patients who underwent drug susceptibility testing were found to have MDR-TB, and the rate of multidrug resistance was 2.1% in new patients and 14.2% in previously treated patients ([@bib22]). According to WHO 2018 data, MDR-TB ratio is 3.5% of new TB cases and 18% of previously treated cases globally ([@bib30]). The rates of MDR-TB in the studies made in different regions of Turkey vary between 2.2--14.7% ([@bib24]; [@bib7]; [@bib1]; [@bib12]). In our study, resistance to more than one drug was detected in 51 (21.88%) isolates. MDR-TB ratio was 13.7% (7/51) among resistant strains and 3% (7/233) among all strains isolated, and this rate was consistent with other studies.

Today, the number of patients with tuberculosis has increased, possibly due to changes in recent years such as social and economic turmoil, increased number of migrant patients, changes in the practices healthcare system, and drug-resistant *Mycobacterium* isolates. Therefore, a correct and rapid diagnosis and supervised treatment concepts should be reviewed and applied to prevent susceptible strains from gaining resistance and stopping the further spread of resistant strains. Our data indicate that NTMs species will probably be more frequently encountered in the future. Furthermore, we can speculate that drug resistance will continue to be an important problem in patients with tuberculosis.

One of the limitations of this study was that the patients and the isolates were selected from a single centre albeit it was a large tertiary care centre. This might have influenced the information gathered. However, it should also be stated that the medical centre where the study is conducted is located in the heart of the old city of Istanbul, where the immigrants are concentrated.

Data from this study indicate that the frequency of isolations of *M. tuberculosis* complex in the population seems to form a bimodal distribution, one in the third decade of life and the other in the 7th. Obviously, our study is not designed to address this particular demographic aspect of *M. tuberculosis* infection in detail. However, we judge that providing such data would be a useful addition to a study aiming to capture a current picture of *Mycobacterium* species in an endemic country.

In conclusion, this investigation demonstrates that tuberculosis is still a growing public health threat in Istanbul, Turkey. We do not know how much of this increase is the result of the recent high immigration rates. The drug resistance rates also seem to be on the rise. Therefore, rapid and accurate laboratory services are imperative in combatting such a growing public health menace. Our study demonstrates that the liquid culture is superior to the solid media for the recovery of *Mycobacterium* species and, hence, should be included in the routine mycobacteriology laboratory procedures. Collectively, these results underscore the need for the marshaling preventive public health efforts on this age-old concern.
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